Adalimumab on the map in ankylosing spondylitis.

Improvements in ankylosing spondylitis previously demonstrated with adalimumab have now been shown to persist with long-term treatment, and the agent has also demonstrated excellent efficacy in a real-life clinical setting, according to study results presented at this year's joint meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) [Boston, Massachusetts, US; November 2007]. In an open-label extension to the phase III ATLAS study, the effectiveness of adalimumab was found to he maintained for up to 2 years, with sustained improvements observed in spinal mobility throughout this time. Furthermore, in a study conducted in a real-life clinical setting, adalimumab was effective and well tolerated, and was also associated with significant reductions in uveitis flares, and with improvements in peripheral arthritis and enthesitis. [ABSTRACT FROM AUTHOR]